MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 15 2022 - 9:00AM
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading
commercial cell-engineering company focused on providing enabling
platform technologies to advance innovative cell-based research as
well as next-generation cell therapeutic discovery, development and
commercialization, today announced that, on April 11, 2022, the
Compensation Committee of MaxCyte’s Board of Directors granted
stock options to purchase (i) an aggregate of 54,000 shares of
MaxCyte’s common stock to four (4) newly hired employees and (ii)
500,000 shares of MaxCyte’s common stock to Cenk Sumen, MaxCyte’s
newly hired Chief Scientific Officer. Each of the foregoing stock
options were granted as material inducements to employment with
MaxCyte in accordance with Nasdaq Listing Rule 5635(c)(4) and were
granted under the MaxCyte, Inc. 2021 Inducement Plan (the “2021
Inducement Plan”).
The stock options have a ten-year term and an
exercise price of $5.670per share, which is equal to the closing
price of MaxCyte’s common stock on April 11, 2022. Each option will
vest over a four-year period, with 25% of the shares vesting after
12 months and the remaining shares vesting monthly over the
following 36 months, subject to the employee’s continued employment
with MaxCyte on such vesting dates. The options are subject to the
terms and conditions of the 2021 Inducement Plan and the terms and
conditions of an award agreement covering the grants.
About MaxCyteMaxCyte is a
leading commercial cell-engineering company focused on providing
enabling platform technologies to advance innovative cell-based
research as well as next-generation cell therapeutic discovery,
development and commercialization. Over the past 20 years, we
have developed and commercialized our proprietary Flow
Electroporation® platform, which facilitates complex engineering of
a wide variety of cells. Our ExPERT™ platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™ GTx™and VLx™; a
portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio.
MaxCyte Contacts:
US IR
AdviserGilmartin GroupDavid Deuchler,
CFA |
+1
415-937-5400ir@maxcyte.com |
|
|
Nominated Adviser and
Joint Corporate BrokerPanmure GordonEmma Earl / Freddy
CrossleyCorporate BrokingRupert Dearden |
+44 (0)20 7886 2500 |
|
|
UK IR
AdviserConsilium Strategic
CommunicationsMary-Jane ElliottChris Welsh |
+44 (0)203 709
5700maxcyte@consilium-comms.com |
|
|
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jul 2023 to Jul 2024